Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

4-Letter Word: US FDA's Biosimilars/Biologics Distinction

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration wants all biologics, including biosimilars, to carry a unique four-letter suffix as part of the nonproprietary names (INNs) of the active drug substance, the agency revealed on Aug. 27 in a draft guidance document and a proposed rule – giving a big win to innovator manufacturers, which have insisted on imposing distinguishable names on the copycats1,2.

Advertisement
Advertisement
UsernamePublicRestriction

Register